Biogen (BUE:BIIB) Gross-Profit-to-Asset %

: 31.70% (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Biogen's annualized Gross Profit for the quarter that ended in Mar. 2023 was ARS1,422,518 Mil. Biogen's average Total Assets over the quarter that ended in Mar. 2023 was ARS4,487,954 Mil. Therefore, Biogen's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2023 was 31.70%.

Biogen Gross-Profit-to-Asset % Historical Data

The historical data trend for Biogen's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

62.45

57.53

52.17

40.59

40.55

Biogen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Gross-Profit-to-Asset %																30.87	36.49	35.02	34.96	31.70

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen Gross-Profit-to-Asset % Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Biogen's Gross-Profit-to-Asset % falls in comparison to its industry or sector. The grey bar indicates the Gross-Profit-to-Asset %'s extreme value range as defined by GuruFocus.

Biogen Gross-Profit-to-Asset % Calculation

Biogen's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	1323613.478	/	( (2411368.476	+	4116494.751)	/ 2 )
	=	1323613.478	/	3263931.6135
	=	40.55 %

Biogen's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Mar. 2023 ))	/ count )
	=	1422518.072	/	( (4116494.751	+	4859414.033)	/ 2 )
	=	1422518.072	/	4487954.392
	=	31.70 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Biogen Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Biogen's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BUE:BIIB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany BIIB34:Brazil BIIB:Austria

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

http://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.